Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
2 hrs 15 minutes into the trading day, we have 180,200 shares traded.
NITE, CANT & VERT will control the bid and ask all today in anticipation of earnings.
*NEWS* USRM Chief Science Officer to Present at Paleo f(x) Ancestral Healing Conference in Austin, Texas
PR Newswire
SUNRISE, Fla., March 20, 2018
SUNRISE, Fla., March 20, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC:
USRM), a leader in the development of proprietary, physician-based stem cell
therapies and novel regenerative medicine solutions, is pleased to announce
its Chief Science Officer, Dr. Kristin Comella, has accepted an invitation to
present at the 2018 Paleo f(x) Ancestral Healing Conference Friday, April 27,
at the Palmer Events Center in Austin, Texas.
(PRNewsfoto/U.S. Stem Cell, Inc.)
Dr. Comella will present "Regenerative Medicine: The Future of Medicine is
Here," at 4:25 p.m. CST at the Kegenix Paleo On Ramp Stage. Her presentation
will be livestreamed on the USRM facebook page, follow to receive a live
notification.
Dr. Comella will also participate in a Mastermind Panel entitled "Alt-Med: New
Paradigms in Health and Wellness," with several other world leaders in
innovative health, including Dr. Joseph Mercola, Neurologist Dr. David
Perlmutter, Naturopath Dr. Harry Adelson, epigenetic pioneer Dr. Ben Lynch and
functional medicine expert Dr. Michael Ruscio, on Friday, April 27 at 5:35
p.m. CST at the ID LifeWellness Keynote Stage. The topic will explore how
traditional western medicine has been undeniably successful in battling
communicable diseases and acute trauma, but how do we navigate its failure to
deal with the diseases of modernity that plague us now?
"I am honored to have the opportunity to participate in the Paleo f(x)
conference with such esteemed colleagues, and to share with the audience and
other world innovators our latest developments on autologous stem cell therapy
and stromal vascular fraction," said Dr. Comella. "It will be a pleasure to
participate in this conference, which will feature a very interesting presence
of leading health practitioners from around the world."
Dr. Comella, who has more than 20+ years' experience, is recognized worldwide
by her peers as an innovator and world leader in the development and clinical
practice of stem cell products and therapies. She has also been instrumental
in developing and bringing to market USRM's proprietary Adipocell™ product, a
stem cell kit which enables physicians to separate potent stem cells from a
patient's own fat, a naturally occurring tissue in the body which happens to
contain a robust supply of stem cells.
Once harvested, through a minimally invasive liposuction procedure that is
performed while the patient is comfortable but fully awake, the stem cells are
then re-injected intravenously or applied directly to a damaged tissue for a
more targeted application.
In January, the Company announced Adipocell™ reached sales of 10,000+ kits
worldwide.
Autologous stem cell treatments harvested from the patient's own fat can
provide healthier alternatives to the use of pharmaceuticals for treating
chronic pain and degeneration. Chronic pain has been the source of a national
opioid epidemic which The New York Times reported in October is the leading
cause of death for Americans under 50.
USRM has been involved in more than 10,000 stem cell procedures in the past 19
years for a variety of indications including orthopedic, autoimmune,
degenerative and neurological diseases. USRM also trains and certifies
physicians in stem cell therapy -- to date, more than 700+ physicians
worldwide -- and has engaged with more than 287 clinics.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine /
cellular therapy industry specializing in physician training and certification
and stem cell products including its lead product Adipocell™, as well as
veterinary stem cell training and stem cell banking and creation and
management of stem cell clinics. To management's knowledge, USRM has
completed more clinical treatments than any other stem cell company in the
world.
Forward-Looking Statements: Except for historical matters contained herein,
statements made in this press release are forward-looking statements. Without
limiting the generality of the foregoing, words such as "may", "will", "to",
"plan", "expect", "believe", "anticipate", "intend", "could", "would",
"estimate", or "continue", or the negative other variations thereof or
comparable terminology are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and
other factors, which may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements and
represent our management's beliefs and assumptions only as of the date hereof.
Except as required by law, we assume no obligation to update these
forward-looking statements, even if new information becomes available in the
future. The Company's business and the risks and uncertainties of the business
are described in its filings with the Securities and Exchange Commission which
can be found at sec.gov.
Media Contact: U.S. Stem Cell, Inc.
13794 NW 4th Street, Suite 212
Sunrise, Fl 33325
Phone: 954.835.1500
Email: usstemcell@us-stemcell.com
Cision View original content with
multimedia:http://www.prnewswire.com/news-releases/usrm-chief-science-officer-to-present-at-paleo-fx-ancestral-healing-conference-in-austin-texas-300616453.html
SOURCE U.S. Stem Cell, Inc.
https://www.bloomberg.com/press-releases/2018-03-20/usrm-chief-science-officer-to-present-at-paleo-f-x-ancestral-healing-conference-in-austin-texas
Earnings release Wednesday, March, 21st 2018
https://www.marketbeat.com/stocks/OTCMKTS/USRM/
US Stem Cell is scheduled to release their next quarterly earnings announcement on Wednesday, March, 21st 2018.
The company says it has seen an “explosive demand for stem cell treatments,” generating a 92 percent increase in revenue for the first nine months of 2017 compared with the same period in 2016.
Watch out Big Pharma..
Great Article.. Thanks
Earnings happen each quarter, so volatility is predictable. Prepare for earnings instead of ‘rolling the dice’, earnings offer an opportunity for profits because they’re a predictable period of high volatility.
2 trading days before earnings.
Manipulation Day. MM's with all these 1000 & 400 trades today. Signaling back and forth with each other. Trying to catch people with their stop losses. NITE, CANT & VERT controlled the bid and ask all today.
VERT & CANT, sitting on the ask @ .0595 with their bottomless 10K shares.
Multiple sclerosis: Skin cells may help to repair nerve damage
Published Friday 23 February 2018
By Honor Whiteman |
Fact checked by Jasmin Collier
A personalized treatment for multiple sclerosis may be one step closer, thanks to a new study that reveals how a person's own skin cells could be used to repair the nerve damage that the disease causes.
Researchers reveal how neural stem cells derived from skin may help to treat MS.
Led by scientists at the University of Cambridge in the United Kingdom, the study took skin cells from adult mice with multiple sclerosis (MS) and then reprogramed them into neural stem cells (NSCs).
These "induced neural stem cells" (iNSCs) were transplanted into the rodents' cerebrospinal fluid.
There, they reduced inflammation and repaired damage to the central nervous system (CNS).
Lead study author Dr. Stefano Pluchino, of the Department of Clinical Neurosciences at the University of Cambridge, and team believe that their strategy could offer a promising treatment for MS and other neurological diseases.
The researchers recently reported their findings in the journal Cell Stem Cell.
MS is a progressive neurological disease that is estimated to affect more than 2.3 million people across the globe.
While the precise causes of MS remain unclear, "an abnormal immune system response" is thought to be involved. Such a response leads to inflammation in the CNS, which causes the destruction of myelin, or the fatty substance that protects nerve fibers.
As a result, the nerve fibers become damaged. This disrupts neuronal signaling and triggers the neurological symptoms of MS, including tingling in the face or extremities and problems with movement, balance, and coordination.
Using stem cells to treat MS
Previous research has investigated the use of NSCs for the treatment of MS. NSCs are stem cells that have the ability to transform into different types of cell in the CNS — including neurons and glial cells.
However, there are some barriers to this strategy. As Dr. Pluchino and colleagues note, NSCs are derived from embryos, and it would be hard to obtain them in high enough quantities to sustain clinical treatment.
New MS drugs could be in the pipeline, thanks to a brain-repairing protein.
It is also possible that the immune system would see embryo-derived NSCs as foreign invaders and try to destroy them.
As such, researchers have turned their attention toward iNSCs, or NSCs that can be developed by reprogramming adult skin cells. Importantly, since these cells would be derived from the patients themselves, the risk of an immune system attack would be significantly reduced.
To test whether iNSCs could be a feasible treatment option for MS, Dr. Pluchino and his colleagues tested them on adult mice that had been genetically engineered to develop the condition.
The team took cells from the skin of the mice and reprogramed them into NSCs, effectively making iNSCs. Next, the team transplanted these iNSCs into the cerebrospinal fluid of the mice.
Study yields promising findings
The researchers found that this led to a reduction in levels of succinate, which is a metabolite that the team found is increased in MS. This increase prompts microglia — a type of glial cell found in the CNS — to trigger inflammation and cause nerve damage.
By reducing succinate levels, the iNSCs reprogrammed the microglia — which, in turn, reduced inflammation and brain and spinal cord damage in the mice.
Of course, human clinical trials are needed before iNSCs can be considered as a suitable treatment for MS, but this latest study certainly shows promise.
"Our mouse study suggests that using a patient's reprogrammed cells could provide a route to personalized treatment of chronic inflammatory diseases, including progressive forms of MS."
–Dr. Stefano Pluchino
"This is particularly promising," Dr. Pluchino adds, "as these cells should be more readily obtainable than conventional neural stem cells and would not carry the risk of an adverse immune response."
https://www.medicalnewstoday.com/articles/321022.php
Good start .06 volume 507.4 K in first 3 minutes
Stem Cells and Antibodies in Drug Discovery Europe 2018
Date: Thursday, 24 May 2018 - Friday, 25 May 2018
Location: Cambridge, UK
Keynote Speakers
Robert Williams
Chief Drug Development Scientist, Cancer Research UK
Stefan Dubel
Stefan Dubel
Full Professor and Director, Technische Universität Braunschweig
Matthew Daniels
Wellcome Trust Intermediate Clinical Fellow, Honorary Consultant Cardiologist, University of Oxford
Paul French
Professor, Department of Physics and Photonics Group, Imperial College London
Stephen Helliwell
Senior Investigator, Novartis Institutes for BioMedical Research
Gary Gintant
Gary Gintant
Research Fellow, Abbvie
David Hay
Professor, University of Edinburgh
Overview
Stem Cells and Antibodies in Drug Discovery 2018 and Antibodies in Drug Discovery 2018 is held co-located and concurrently with High-Content & Phenotypic Screening 2018 which explores the emerging trends and technologies impacting Drug Discovery, circa 2018.
Delegates and Exhibitors Receive Full Access to Both Conference Tracks and the Scientific Content and Presentations are Intertwined Between These Tracks
Stem Cells in Drug Discovery 2018: Hear from and network with researchers who are currently screening for efficacy and toxicity using iPS cell lines, and those responsible for developing the techniques and technologies. There will also be discussions on industry and regulatory developments that are shaping the future of stem cell usage in drug discovery.
Antibodies in Drug Discovery 2018: The focus is to explore the latest developments in the design and engineering of antibodies in relation to the burgeoning field of biotherapeutics. Topics to be addressed include, engineering challenges and techniques, new technologies and business hurdles when developing antibodies, the latest developments in autoimmune and infectious disease research. If you work in antibody drug discovery research you will benefit from the expert knowledge of academic and industry leaders, whilst networking with the technology providers.
https://selectbiosciences.com/conferences/index.aspx?conf=SCABDDEU2018
Earnings week, should be interesting. GLTA
Health Letter, December 2017
Michael Carome, M.D.
drug dealing transaction for pills
shutterstock/Syda Productions
On Oct. 26, 2017, the U.S. Department of Justice (DOJ) announced the arrest of John Kapoor, the billionaire founder and majority owner of Insys Therapeutics, the drug company that markets fentanyl sublingual spray (SUBSYS). Kapoor has been charged with “leading a nationwide conspiracy” to profit by bribing doctors to inappropriately prescribe the company’s fentanyl spray product and by defrauding health insurers.
Kapoor joins six other former Insys senior executives and managers — including former CEO and president Michael Babich — who were initially indicted in December 2016 on similar conspiracy and fraud charges. Most, including Kapoor, were charged under the Racketeer Influenced and Corrupt Organizations Act, which originally was intended to target criminal organizations such as the Mafia (see here and here).
Subsys, the first of two drugs marketed by Insys, is a rapid-acting, highly addictive, dangerous opioid that is sprayed under the tongue. The Food and Drug Administration approved the drug in 2012 only for treating breakthrough pain in adult cancer patients who are not responding adequately to other opioids.[1]
Under the brazen scheme allegedly orchestrated by Kapoor and his co-conspirators, company employees paid bribes and kickbacks to health care practitioners in multiple states to entice them to prescribe Subsys to large numbers of patients, most of whom were not diagnosed with cancer. Marketing drugs for such unapproved — also known as “off-label” — uses is illegal.
The government also alleged that the Insys executives conspired to mislead and defraud health insurance companies that resisted approving payment for Subsys when it was prescribed to non-cancer patients. To that end, they established a “reimbursement unit” within Insys that was dedicated to obtaining preauthorization for such prescriptions directly from insurers for these off-label uses.
Other generally lower-ranking Insys employees already had been charged in the conspiracy, and at least two pleaded guilty earlier this year (see here, here and here). Several doctors also have been convicted of or pleaded guilty to accepting kickbacks from Insys in exchange for prescribing Subsys (see here and here). The indictment of Kapoor reveals that the rot extended to the very top of the company.
Commenting on the indictment of Kapoor and his co-conspirators, Harold Shaw, special agent in charge of the FBI’s Boston Field Division, said, “As alleged, these executives created a corporate culture at Insys that utilized deception and bribery as an acceptable business practice, deceiving patients, and conspiring with doctors and insurers. The allegations of selling a highly addictive opioid cancer pain drug to patients who did not have cancer, make them no better than street-level drug dealers. Today's charges mark an important step in holding pharmaceutical executives responsible for their part in the opioid crisis.”
Likewise, Drug Enforcement Agency Special Agent in Charge Michael J. Ferguson noted, “Pharmaceutical companies [like Insys] whose products include controlled medications that can lead to addiction and overdose have a special obligation to operate in a trustworthy, transparent manner, because their customers’ health and safety and, indeed, very lives depend on it.”
The DOJ and the many other federal agencies involved in the investigation of Insys should be applauded for aggressively pursuing the most senior company executives who hatched this conspiracy. If convicted, they deserve lengthy prison sentences for recklessly endangering thousands of patients across the U.S.
Feeling like 40 again would be awesome.. The future looks promising..
“I was thinking about how people seem to read the bible a lot more as they get older, and then it dawned on me—they’re cramming for their final exam.”
? George Carlin
Life-changing results... Many people will benefit, and it's only the beginning..
There have been countless examples of the manipulation of published research at the hands of pharmaceutical companies in recent years. This is why Harvard Professor of Medicine Arnold Symour Relman told the world that the medical profession has been bought by the pharmaceutical industry. It’s why Dr. Richard Horton, Editor in Chief of The Lancet, recently stated that much of the scientific literature published today is simply untrue. It’s why Dr. Marcia Angell, former Editor in Chief of The New England Journal of Medicine, said that the “pharmaceutical industry likes to depict itself as a research-based industry, as the source of innovative drugs. Nothing could be further from the truth.” And it’s why John Ioannidis, an epidemiologist at the Stanford University School of Medicine, published an article titled “Why Most Published Research Findings Are False” which subsequently became the most widely accessed article in the history of the Public Library of Science (PLoS).
For decades Big Pharma has controlled and manipulated the media to keep certain truths hidden. They’ve shamelessly and easily bribed politicians. They’ve lied to government health officials, and they are repressing scientists who advocate the safety of stem cells. Stem cells and USRM are the future.
However it appears what they do not lack is intellectual capacity. A scientific paper regarding intramyocardial implantation, co-authored by Kristin Comella, Chief Science Officer of US Stem Cell Inc (OTCMKTS:USRM), has been recognized as one of the most influential papers of 2016 according to Altmetric.com. This is not the first time that Kristin Comella has been recognized for her contributions to stem cell science. She was also named #24 on Terrapin’s list of top 50 Global Stem Cell Influencers. She was also listed at #1 on the Academy of Regenerative Practices list of Top Ten Stem Cell Innovators. Mr. Comella also led the team that achieved the first ever FDA approval for a clinical trial for a heart product that used a combination of cell and gene therapies.
http://stocknewsunion.com/peer-recognition-for-us-stem-cell-inc-otcmktsusrm/5733/
According to President and Chief Executive Officer of U.S. Stem Cell Inc, Mike Tomas, “U.S. Stem Cell, Inc. continues to increase revenue, decrease liabilities, and decrease operating expenses.”
If you're competing with the best, you will rise up to that level.
Interesting article.. Thanks
Thank You For Sharing. We appreciate you taking the time to tell us your personal journey. Please keep us informed. Best to you and your family..
Have a good weekend. Next week will be interesting..
I saw that 4400 share trade..
Closing Price $0.0597 +0.0037 (6.61%) MM's setting up for next week..
Market Maker Manipulation
Cross-Trading is the control by one or only a few brokers who match purchases and sales to drive up or down the stock price which ever way benefits them. According to Forbes' Article on Market Makers this is the hallmark of penny stock manipulation
Boxing where a broker will position himself on both the ask and the bid, which is the heart of penny stock manipulation according to Business Week's 1996 Article: The Mob on Wallstreet eliminating competing market makers and allowing only cooperating brokers to bid on stocks, the result is a kind of rigged auction.
Stock Call Signals which appear to be small share blocks of stock typically 100, 200 and 300 to get a supply of stock another MM or broker to help with an "Oversell", which is the amount of shares sold by a Market Maker that were not bought. Market Makers buy on the bid and selling on the ask, which is an automatic buy low sell high advantage for them same as being the house in a casino.
USRM VS. INDUSTRY +160.59% 52-Week Change
How to Trade During Earnings Season
by Dr. Charles B. Schaap
Earnings season can be a more difficult time to trade due to the potential volatility that may occur after and earnings announcement. While there are no hard and fast rules for how to trade during earnings season, there are a few general guidelines which can help you survive and thrive. Much depends on whether or not you own the stock that is releasing the earnings report.
It is important to understand that stocks can fall on good earnings and rise on poor earnings. The market can be fickle at times. But remember the market is always right. Therefore, the key is to watch how the market reacts to the earnings report. How the market reacts will tell you what you need to know about how to establish or manage a stock position.
Keep in mind that earnings may be announced before the open, during market hours, or after the close. Reports released before the open will often result in the stock being up/down in premarket trading and throughout the day. Earnings released after the close may see the stock move up/down in after-hours trading and the next morning's session. Reports released during the market's normal trading hours can be highly volatile, especially in the stocks with lower average trading volume.
The basic principle about earnings announcements is to pay close attention to how the market responds AFTER the earnings are announced. It is generally best not to buy a stock just before the announcement since this is a higher risk period. If you do want to trade the potential volatility, I think it's better to use options; option prices are more reactive to volatility and offer lower capital risk.
If you have a stock in your watchlist that is reporting earnings, you should already know the trigger price and the stop loss guidelines. You are prepared. In this case, buying the stock if it breaks out makes it like any other trade, except you must beware of the potential volatility. There may be a wide range bar that develops on high volume. Don't be in rush to chase price; wide range bars tend to pull back to the 10 SMA or move sideways while the moving average catches up.
If you already own a stock when earnings are announced, you will want to pay close attention to your stop loss order. You may get stopped out if there is high volatility, and it sometimes can't be avoided. This will most often occur if there is a negative surprise to the earnings. If that's the case, you may want to be out of the stock anyway. If you give the stop loss extra room on earnings announcements, don't allow more than a -10% loss. You should always have a resting stop loss order in place.
Pay careful attention to stock positions that do not have a profit cushion when earnings are announced. (A profit cushion means you have an unrealized gain in the position.) Positions without a profit cushion may lack significant profits because the BIGs have information about what the earnings are likely to be, and they may have been avoiding the stock, so it has not advanced. Be very careful about earning announcements when your stock has an unrealized loss.
If you have a profit cushion, it makes things easier because you're not risking your capital, only your profits. Always pay attention to the price action leading up to the earnings announcement. There are generally clues to the strength or weakness of the stock which tells whether the BIGs are quietly making their way to the exits. Even “surprise” weak earnings is often telegraphed by the price action leading up to the announcement.
Many times the stock will gap up after a very favorable or surprisingly good earnings report. When this happens, trade it like a gap trade with special attention to the volume. Strong gaps have volume that is generally greater than 1.5 times the average volume (50-day). It's probably a good idea to let the price settle down during the first hour of trading to be more certain that the gap will hold.
If the stock shows signs of weakness after the earnings are announced, you will want to avoid it. If heavy selling volume comes into the stock, it means the BIGs are selling off shares and may start to dump the stock. If you sell, and it ends up being a temporary selloff, then you will have the opportunity to reenter at a lower price.
In summary, remember to study the price action leading up to the earnings announcement for clues. How the stock reacts to the announcement is the most important thing, not necessarily how good or bad the report is perceived to be. Only buy stocks from your watchlist since these stocks have been researched already. Always know when earnings are going to be announced on a stock you already own, and make sure your risk is managed.
http://www.tradelikeapro.com/public/How-to-Trade-During-Earnings-Season.cfm
Trick #1: Giving Phony Sizes
When a trade is called into the floor of the New York Stock Exchange (NYSE), it is immediately routed to a specialist in the stock, who often has limited interest in the individual trade. Because the specialist is being inundated by traders, he simply wants to find a buyer or a seller for your stock as soon as possible. Essentially, he is an intermediary, who sometimes takes positions in stock, but is really there to function as a liquidity provider.
However, Nasdaq market makers, routinely take positions in stocks, both long and short, and then turn them around for a profit, or a loss, later in the day. They provide liquidity, but they are also more focused on capitalizing on your lot of stock by buying it for their own trading account and then flipping it to another buyer. In any case, market makers will sometimes post phony sizes in order to lure you into buying or selling a stock.
For example, market makers may post a bid and an offer that looks something like this:
$10-$10.25 (75x10)
This means that they will buy 7,500 (multiply 75x100) shares of your stock at $10 per share and they will sell 1,000 shares of stock at $10.25. They are obligated under Nasdaq rules to honor those sizes. However, there is a chance that the market maker already owns a position in the stock, and by posting a bid for 7,500 shares, he is merely looking to fool brokers and investors into thinking that there is big demand for the stock and that it is moving higher. (To read more on this subject, see Electronic Trading Tutorial and Markets Demystified.)
Note on this subject: While actions such as this may be frowned upon by the National Association of Securities Dealers (NASD) - they are still fairly common in practice. Also, if someone tries to sell 7,500 shares to the market maker, he must buy them because his bid is posted.
So what happens? Most brokers will simply pay $10.25 for the stock just to get the trade done, but in reality, the purpose of posting a big bid was to sell the market maker's 1,000 shares at $10.25 to the unsuspecting broker. The trick worked! Incidentally, the same trick can be used in reverse on the sell side of the equation. The market maker may show a big offer of say 10,000 shares. Brokers see this, think that the market maker is looking to unload a big block of stock, and quickly sell their shares at the bid price (which, using the above example, is $10). In this case, the trick works again because the market maker fools the broker into selling his shares at $10, precisely where he (the market maker) wanted to buy them.
How to Avoid this Trick: Watch a stock trade before buying or selling it. Learn the players in the stock. By watching the action on a "level 2" or "level 3" screen, you can tell who is accumulating shares or unloading them. With this knowledge, you\'ll have a better idea of whether the sizes the market maker posts are real. (To learn more, read Introduction To Level II Quotes.)
Read more: How Brokers Can Avoid A Market-Maker's Tricks https://www.investopedia.com/articles/financialcareers/06/mmakertricks.asp#ixzz59vsZ1yEM
Follow us: Investopedia on Facebook
https://www.investopedia.com/articles/financialcareers/06/mmakertricks.asp
When 100 Actually Means 25,000
When watching larger stocks, market makers from large firms will often bid for 100 shares when they actually want several thousand shares.
Market makers are in the game to make money as well as execute orders for their firm's clients.
If you do see a huge bid or ask - thousands of shares where it's not usual it's often a fake. That is, they really don't want to execute that trade but are actually trying to scare others and to move the stock the opposite way that their bid or ask would indicate. If the stock happens to trade closer and closer to that larger bid or ask, it will usually disappear. Smaller stocks and penny stocks are rife with that type of dishonest manipulation on OTC markets.
Market makers will almost never show their hand to let others know what order they are working. For instance, let's say a market maker for at a major firm receives an order to purchase 25,000 shares of a stock at a $5.00 limit for an institutional client. He will never bid for the full 25,000. He will place a 100 or 200 share bid at $5.00 or lower. Why? If the market maker places all 25,000 shares at the bid at $5.00, another market maker with shares to sell could "hit" that bid and sell him everything at $5.00. The trade is over; the bidding market maker has just bought all 25,000 at $5.00. However, using smaller bids and some patience will usually mean he can get shares a bit cheaper. With a 25,000 order, a difference of just a few cents can result in thousands of dollars.
The market maker with the bid will put up only 100-200 to see if any fish bite. If they do, he'll remember who sold him those and move his bid down to $4.95, $4.90, etc. and see if he can get more there. If he does, great, he'll keep working the price down as far as he can go to get the shares as cheaply as possible.
Perhaps he now has 25,000 shares with an average price of $4.80. Now that the market maker has 25,000 shares, he can then sell them to his customer at $4.90. At $4.90, the customer is happy because he would have paid up to $5.00 and the market maker is happy because he sold the shares to the client $0.10 higher than it cost him and he made a tidy profit of $2,500.
Market makers will almost never post a bid or ask for more than just a few hundred shares no matter how large their true need is. So if you do see a market maker from a large firm posting a bid for 500 shares, there's usually thousands of shares behind that. Unless he's selling signals and not selling just stock.
http://falconstocks.com/articles/readingmarketmakers.html
Regenerating the Body With Stem Cells – Hype or Hope?
Reviews
Melanie De Almeida on 11/07/2017
When the Japanese researcher Shinya Yamanaka managed to reprogram adult cells into an embryonic-like state to yield induced pluripotent stem cells (iPSCs), this was supposed to herald a revolution in regenerative medicine. But 10 years after their discovery, a therapeutic breakthrough is still outstanding.
“The overall stem cell therapy field has failed today to show a very clear cut clinical benefit,” told me Georges Rawadi, VP for Business Development at Celyad. “The field now needs some significant success to attract attention.”
Even though investors prefer placing their bets on the hot T cell therapies these days, some stem cell technologies such as iPSCs are starting to get traction as big industry players are exploring the territory. Last year, Bayer and Versant threw $225M into the pot to launch BlueRock Therapeutics, a regenerative medicine company that plans to develop iPSC-based therapies. A year before, Fujifilm spent $307M to acquire the iPSC company Cellular Dynamics.
Although a big success story is still lagging behind, recent advances in the field argue that stem cells indeed have the potential to translate into effective therapies for currently intractable diseases. Here’s an overview of what biotech’s stem cells are up to!
The Cell Therapy Prototype
Stem cell treatment is not a new concept – hematopoietic stem cells (HSCs) were described as early as the 1960s and bone marrow transplants have been used to treat blood cancer for decades.
“The reason that we get excited about stem cell therapies comes from our experience with the hematopoietic stem cells. If you want to see what a mature stem cell therapy is like, you only need to look at bone marrow transplantation” explained James Peyer, Managing Partner at Apollo Ventures, who has a Ph.D. in stem cell biology.
According to Peyer, the hematopoietic stem cell field is one of the most active areas in the stem cell world right now, mainly fueled by our advances in the gene editing space. Tools like CRISPR and TALEN allow for the genetic modification of a patient’s own bone marrow stem cells, which can then be expanded and returned to the patient for the correction of a genetic defect.
Stem cell therapy review gene editing
Last year, regulators gave green light to one of the first therapies of this kind. Strimvelis, developed by GSK, consists of an ex vivo stem cell gene therapy to treat patients with the very rare type of Severe Combined Immunodeficiency (SCID). Using the patient’s own cells avoids the risk of graft versus host disease (GvHD), which still affects around 30% of people receiving a bone marrow transplant.
Small wonder that the CRISPR companies, CRISPR Therapeutics, Editas, and Intellia are all active in this field, with preclinical programs in a number hematological diseases.
Mesenchymal Stem Cells – Trial and Error
To date, the most prominent stem cells in the clinic are mesenchymal stem cells (MSCs), which are moving through more than 300 registered clinical trials for a wide array of diseases. These cells are able to form a variety of tissues including bone, cartilage, muscle or fat, and can be readily harvested from patients or donors for use in autologous or allogeneic therapies.
While MSCs have deluded the biotech scene with good safety profiles in clinical trials, their actual regenerative potential remains controversial, and there have been a great number of clinical failures, which many blame on a lack of demonstrated mechanisms of action.
As Peyer explained, “The problem here is that, as opposed to other adult stem cells, the MSC has been unclearly defined. We know roughly what it does but we don’t fully understand the molecular mechanisms driving these cells. On top of being unclearly defined, the regenerative powers of MSCs have been massively over-claimed in the past.”
Another reason for the lack of clinical benefit has also been attributed to the use of undifferentiated MSCs, as Rawadi explained to me. The Belgian biotech Celyad, which has been pioneering cell therapy in the cardiovascular space, is using bone-marrow derived autologous MSCs and differentiates them into cardiomyocyte precursors to produce new heart muscle in patients with heart failure.
Although the company missed its primary endpoint in a phase III trial last year, Celyad has staked out a patient subpopulation that showed significant improvement. Its technology still has the confidence of the FDA, which just handed out a Fast Track designation and Celyad is now planning a refined Phase III trial.
Modulating the Environment
One of Celyad’s major competitors, Australian Mesoblast, is forging ahead using allogeneic MSCs with Phase III programs in heart failure, chronic low back pain (CLBP) due to disc degeneration, as well as a range of inflammatory conditions including GvHD and rheumatoid arthritis.
Although the ability of MSCs to regenerate tissues remains questionable, the Mesoblast’s approach hinges on a body of evidence showing that MSCs can suppress inflammation and mobilize endogenous repair mechanisms through indirect effects on immune cells.
Stem cell therapy review
Indeed, the first-ever approved stem cell therapy, Prochymal, also depends on this mechanism. Prochymal was developed by US-based Osiris Therapeutics and in 2012 received Canadian approval to treat acute GvHD. But after Sanofi opted to shelve its partnership with Osiris prior to FDA approval, the biotech sold out its off-the-shelf stem cell platform to Mesoblast in a $100M deal.
In Belgium, companies like TiGenix and Promethera are also banking on the immunomodulatory properties of MSCs. The companies are developing treatments for patients with Crohn’s disease and liver diseases, respectively.
Moving Towards Regeneration
The ultimate hope for stem cell therapies has been to regenerate damaged or diseased tissues as found in diabetes, heart failure or blindness. Holostem Terapie Avanzate, a spin-off from the University of Modena and Reggio Emilia was the first company to move towards this goal.
Building on 20 long years of research, the biotech has developed Holoclar, the first and only autologous stem cell therapy (apart from bone marrow transplants) to enter the European market. Holoclar is based on limbal stem cells, located in a part of the eye called the limbus, which can be used to restore eyesight in patients that have lost sight due to burn injuries.
Meanwhile, UK-based Reneuron is developing off-the-shelf therapies that aim to restore the cognitive function of patients following a stroke. Backed by no other than Neil Woodford, the company recently raised an impressive €100M to advance its lead therapy to the market.
The biotech’s fetal-derived neural stem cell line CTX was able to significantly reduce the disability of post-stroke patients in a Phase II trial and ReNeuron is now planning to push its candidate into pivotal trials.
“A major question in the space a decade ago was safety. Today, there’s been a lot of trials done that show that safety is not an issue. I think safety is kind of off the table – but efficacy is still a question mark. And that’s what we’re trying to deliver now,” Olav Hellebø, CEO of ReNeuron, told me.
Pluripotency – The Holy Grail
While neural stem cells and other tissue-specific stem cells are able to regenerate the cells of a particular tissue, Embryonic Stem Cells (ESCs) and their engineered counterparts, iPSCs, are capable of making every cell type in the body, a property known as pluripotency. Pluripotent stem cells can also expand indefinitely in culture and their identification unlocked massive expectations for these cells to transform the regenerative medicine field.
Yet, these cells come with significant challenges associated with the safety of the final preparation. “Apart from ethical issues surrounding ESCs, today, a lot of companies have been cautious about using these cells for therapy, because undifferentiated pluripotent cells can drive tumor formation,” explained Rawadi. Since ESCs can, in principle, form every cell type, they can lead to the formation of teratomas.
A major reason for the fairly slow progress in the field is based on the difficulties of directing a pluripotent cell to exactly the cell type that is needed for cell therapy. “We can readily drive the cells from the undifferentiated state to the differentiated state. However, getting those cells to pause anywhere in the middle of this continuum to yield progenitor cells is incredibly challenging,” Peyer explained. Another challenge, he says, is to engraft the cells in the right place to enable them to become fully integrated.
Stem cell therapy review iPSC
Besides initial hurdles, companies like US-based Asterias or ViaCyte are now running the first Phase I/II trials with ESC-derived cells to treat patients with spinal cord injuries and to restore the beta cells in type I diabetes. So far, the eye has been the the dominant organ for many of the first human clinical trials with pluripotent stem cells, where the cells are assessed in diseases such as age-related macular degeneration (AMD) to restore the loss of the retinal epithelium.
Deriving retinal epithelium from pluripotent cells is relatively easy and in fact, researchers in Japan are now running the very first clinical trial using donor-derived iPSCs to treat patients with AMD. For reasons of safety and standardization, the trial is based on an allogeneic approach. However, since this doesn’t offer an exact genetic match, allogeneic therapies raise the prospect of immune rejection, an issue that has been plaguing the use of ESCs.
But the scientists in Japan have contended that iPSC banks could potentially solve this problem. The team in Japan is currently establishing an iPSC bank, consisting of HLA-characterized cell lines from 5-10 different donors, which should match 30–50% of Japan’s population.
“Such haplobanks have the benefits of allogeneic cell therapy, namely cost-effectiveness and standardization, but you still have matching immune systems,” Peyer agrees.
For now, this remains a vision for the future, but the potential seems enormous. As Julian Howell, CMO of ReNeuron, told me, “iPSCs have still got an awful long way to go. For the iPSC program running in Japan, they recently acknowledged that it took about $1.5M and 6 months to treat each patient. It’s a great idea but it’s still got some way to go before it reaches the scale that could get into the clinic.”
https://labiotech.eu/stem-cell-therapy-review/
Volume picking up 887,459
Stem Cell Training
Our mission is to provide doctors regenerative medicine fundamentals, so they can treat their patients with ground breaking therapies. Prior to administering an autologous cellular therapy product, physicians must undergo rigorous training and seek to fully understand the treatments they will offer to their patients. In the foreseeable future, regenerative medicine, especially stem cell therapies, will become the gold standard of care for the treatment of most degenerative diseases and health conditions
Upcoming Training Dates
•January 26 and 27, 2018 – Full
•March 1, 2018
•May 4-5, 2018
•July 13-14, 2018
•September 14-15, 2018
•November 2-3, 2018
https://www.usstemcelltraining.com/
Revenue for the three months ended September 30, 2017, was up 106% to $1.5 million. For the first nine months of the year, it was up 92% to $4.04 million. Gross profit, as a result, increased 158% to $1 million. Cash from operations was also up by 1004% to $1 million from negative $113k in 2016.
Nice Post. Thanks
U.S. Stem Cell's 3rd Q: Increases Revenue, Reduces Debt..
What will the 4th Q tell us ??
Love it..
U.S. Stem Cell Inc. (USRM) REPORT OVERVIEW
On March 6th, 2018, U.S. Stem Cell Inc. closed out the trading session at $0.05 (up 0.21%), compared to the previous day close of $0.05. The volume on the day was 1,440,937 (up 36.35%), compared to the company's previous day volume of 1,056,790. For the twelve months ended December 31st, 2016 vs December 31st, 2015, U.S. Stem Cell Inc .reported revenue of $3.08MM vs $2.19MM (up 40.71%) and basic earnings per share -$0.09 vs -$1.80. U.S. Stem Cell Inc. is expected to report earnings on March 21st, 2018, the report will be for the fiscal period ending December 31st, 2017.
Not much selling going on here.
Degenerative Disc Patients Significantly Improve with USRM’s Adipocell TM Chief Scientific Officer to Present Data at IFATS
Posted by U.S. Stem Cell, Inc
MIAMI, FL –Nov. 28, 2017 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced Chief Science Officer Dr. Kristin Comella will present clinical data demonstrating safety and efficacy of its proprietary Adipocell TM therapy in treating degenerative disc disease — a condition that affects more than 65 million Americans annually 1 — at the Annual Meeting for International Federation for Adipose Therapeutics and Science (IFATS).
Dr. Comella, who is a global leader in the development of revolutionary holistic stem cell therapies, will discuss her paper “Effects of the Intradiscal Implantation of Stromal Vascular Fraction Plus Platelet Rich Plasma in Patients With Degenerative Disc Disease,” on Thursday, November 30, 5:30 p.m., at the Lowes Hotel Miami Beach. Dr.
Comella’s presentation will also be live streamed at www.facebook.com/comella.stem.cell/.
The study, which included 15 patients with degenerative disc disease, featured the use of USRM’s proprietary Adipocell TM therapy following a local tumescent liposuction procedure to remove approximately 60 ml of fat tissue. Adipocell TM kits and enzyme were used to separate and isolate a patient’s own stromal vascular fraction (SVF) which was then delivered into the disc of patients. Patients were then monitored for 6 months for adverse events, range of motion, visual analog scale (VAS), present pain intensity (PPI), Oswestry Disability Index (ODI), Beck Depression Inventory (BDI), Dallas Pain Questionnaire and Short Form (SF)-12 scores. Safety events were also monitored, for a 12-month period.
The procedure demonstrated a strong safety profile with no severe adverse events (SAEs) or complications linked to the therapy they received, and no incidences of infection. Patients who participated in this study experienced statistically significant improvements in several parameters including flexion, pain ratings, VAS, PPI, and short form questionnaires. In addition, both ODI and BDI data was trending positive and a majority of patients reported improvements in their Dallas Pain Questionnaire scores. More importantly, patients overall were pleased with treatment results.
“We are seeing so many advancements in regenerative therapy as a result of the application of stem cells from adipose tissue, and the possibilities are endless,” said Dr. Comella, who co-authored the study along with two colleagues. “We are at a time in history where the potential for effective, regenerative medicine from autologous, stem cell therapy is exploding. At USRM, we are pioneering these new therapies for patients and we continue to publish first in man studies like this one.”
IFATS is a non-profit scientific society currently dedicated to scientific areas of interest related to facilitating the development of treatments for excess body fat, the generation of new fat tissue for reconstruction after cancer or birth-related defects and the use of adipose tissue as a source of mesenchymal stem cells that have the potential to regenerate and repair different body tissues.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician/veterinary training and certification and stem cell products and protocols. USRM also provides stem cell banking for patients and creation and management of stem cell clinics. To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.
1 American Association of Neurological Surgeons & the Congress of Neurological Surgeons.
About U.S. Stem Cell, Inc.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.
http://us-stemcell.com/degenerative-disc-patients-significantly-improve-with-usrms-adipocell-tm-chief-scientific-officer-to-present-data-at-ifats/